title: Decreased efficiency of potassium-titanyl-phosphate laser photoselective vaporization prostatectomy with long-term 5 alpha-reductase inhibition therapy: is it true?
abstract: OBJECTIVE
  5 Alpha-reductase inhibitors (5ARIs) reduce angiogenesis in benign prostatic tissue. This has been postulated to affect the efficiency of the potassium-titanyl-phosphate (KTP) laser during photoselective vaporization prostatectomy (PVP), which has hemoglobin as its primary chromophore. We evaluate KTP laser PVP as treatment for benign prostatic hyperplasia (BPH) in patients on long-term 5ARIs.
  
  
  METHODS
  We prospectively evaluated our initial 12 month KTP laser PVP experience with patients without or with 5ARIs. Transurethral PVP was performed with the use of an 80W KTP side-firing laser system. Voiding trials were performed 2 hours after surgery. International Prostate Symptom Score (IPSS), maximum flow rate (Qmax), and postvoid residual (PVR) were measured preoperatively and at 1, 4, 12, 24, and 52 weeks after surgery.
  
  
  RESULTS
  One hundred sixty consecutive patients were identified, of which 117 were not on a 5ARI and 43 were on either finasteride or dutasteride for at least 6 months. Mean prostate volumes were 72.8 +/- 49.5 cm3 and 70.8 +/- 49.1 cm3 (P = 0.39), respectively. There were no significant differences in the parameters of laser time (32.0 +/- 27.6 minutes and 37.0 +/- 36.2 minutes) and energy usage (97.4 +/- 91.6 kJ and 103.3 +/- 86.0 kJ). All were outpatient procedures with the majority of patients catheter-free at discharge. All patients were able to discontinue their prostate medications after surgery. IPSS, Qmax, and PVR values showed significant improvement within each group, but the degree of improvement between the 2 groups did not show statistical significance.
  
  
  CONCLUSIONS
  Our experience suggests that 5ARIs do not have a detrimental effect on the efficiency and efficacy of KTP laser PVP.
authors: Department of Urology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
authors: Motoo
authors: M
authors: Araki
authors: Po N
authors: PN
authors: Lam
authors: Daniel J
authors: DJ
authors: Culkin
authors: Carson
authors: C
authors: Wong
mesh_terms: D000368:Aged; D001378:Azasteroids / Q000627:therapeutic use*; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors*; D003131:Combined Modality Therapy; D000068538:Dutasteride; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D053844:Lasers, Solid-State / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery*; D013997:Time Factors; D020728:Transurethral Resection of Prostate / Q000379:methods*
chemical_list: D001378:Azasteroids; D018120:Finasteride; D042944:Cholestenone 5 alpha-Reductase; D000068538:Dutasteride